The Serum Institute of India (SII) will buy the vaccine components from Novavax and the two companies will equally split the revenue from the sale of the product, net of agreed costs, Novavax said in a US regulatory filing on Wednesday.
Serum Institute inks deal to produce US-based biotech firm Novavax’s Covid vaccine
